The American enthusiasm for litigation is generally regarded with incredulity by most observers so the lawsuit mentioned below probably shouldn’t come as a surprise, even if the option of cancer with hair - or no cancer, but no hair - seems like a no brainer.
More pertinent is the U.K. statement on HPV vaccinations and to finish off a few words on fibre.
Taxotere Hair Loss Lawsuits Move Forward
(U.S.) Plaintiffs involved in litigation revolving around permanent hair loss from the cancer drug Taxotere recently learned the first case in their multi-district litigation has been set for trial in September 2018.
The plaintiffs involved in the litigation have claimed that they were not warned prior to taking Taxotere that it could cause alopecia, a medical condition in which the immune system attacks hair follicles, resulting in hair loss. While hair loss is often a common occurrence with chemotherapy, plaintiffs have alleged that Taxotere is far more likely to cause permanent alopecia compared to other equally effective cancer drugs.
Taxotere was introduced by Sanofi-Aventis in 1996. It was approved in the U.S. for the treatment of various cancers: breast cancer, advanced stomach cancer, head and neck cancer, non-small cell lung cancer and metastatic prostate cancer. Following the expiration of Sanofi’s patent in 2010, the FDA approved marketing of the generic version of Taxotere – docetaxel – the following year.
According to studies, the risk of permanent alopecia resulting from taking Taxotere is between 6 and 10 percent. Many of the plaintiffs have claimed that they could have taken other equally effective chemotherapy drugs that wouldn’t have resulted in permanent hair loss, but were never warned of the risks by their oncologists. The trauma of permanent hair loss for cancer patients is severe, a constant reminder that they remain victims of the disease.
Teenage boys DENIED ‘life-saving’ HPV jab – putting ‘400,000 a year at risk of cancer’, charity warns
(U.K.) The Joint Committee on Vaccination and Immunisation today advised protecting boys against the cancer-causing virus is "unlikely to be cost effective".
Boys aged 12 and 13 in the UK should not be given the HPV vaccination to protect them from cancer, experts have advised. The decision not to vaccinate boys is part of "interim advice" from the committee, which is responsible for all vaccinations.
It will now go out for consultation before the final advice is published. But campaigners and charities are outraged at the advice, predicting up to 400,000 boys a year could be put at risk.
Girls aged 12 and 13 have been given the vaccination since 2008, as part of a drive to tackle cervical cancer rates. But boys have no protection, despite calls from charities, campaigners, parents and young cancer patients.
In their interim statement, the JCVI said the risk of HPV infection in boys has "already been dramatically reduced by the girls programme and these herd effects will continue to have substantial impact".
The committee responsible for regulating vaccinations say high uptake of the jab among teenage girls is enough to protect boys from the sexually transmitted virus, linked to cervical, penis, anal and head and neck cancers
But, critics have slammed the decision, branding it "shameful and short-sighted".
High Fiber Diet May Reduce Risk of Head and Neck Cancer
A high fiber diet may reduce one's risk of head and neck cancer (HNC), according to research published in the International Journal of Cancer.1
HNC, which is diagnosed in more than 500,000 patients annually, is associated with tobacco- and alcohol-use, though vegetable and fruit intake are associated with a reduced risk of the disease.
The relationship between fiber intake and HNC was, however, previously underreported.
For this pooled analysis, researchers evaluated data from the International Head and Neck Cancer Epidemiology (INHANCE) consortium to determine whether fiber intake affects an individual's risk of HNC.
The authors noted that while fiber may reduce an individual's glycemic load, reduce systemic inflammation, or prevent carcinogens from contact with upper digestive tract epithelia, these results might be explained by the fact that “dietary fiber may simply be an indicator of a better general life-style pattern.”
The study suggests, however, that a “relatively” high fiber intake may reduce the risk of HNC. Further study is warranted.